Redirecting to http://dergipark.org.tr/_fragment?_hash=60qVVG_pe1mP0bbCf4V7E20cPcpiFqg7Ck-_xYZ5-Hk&_path=id%3D1088562%26_format%3Dhtml%26_locale%3Den%26_controller%3DApp%255CController%255CSite%255CArticleController%253A%253AesiArticleStats.
Research Article
BibTex RIS Cite

İnflamatuvar barsak hastalığı olan hastalarda klinik özellikler, tedavi seçenekleri ve komplikasyonların değerlendirilmesi

Year 2022, Volume: 7 Issue: 3, 64 - 70, 31.07.2022

Mücahit Ugar , Fatih Kamış , Yavuz Beyazıt

https://doi.org/10.22391/fppc.1088562

Abstract

Giriş: İnflamatuvar barsak hastalıkları (İBH), genetik olarak duyarlı kişilerde meydana gelen, nedeni tam olarak bilinmeyen, kronik seyirli, bir grup inflamatuvar hastalıktır. Bu çalışmamızda İBH tanısı ile takip edilen hastaların sosyodemografik özellikleri, klinik özellikleri ve uygulanan tedavilerin incelenmesi amaçlandı.

Yöntem: Çalışmamızda Çanakkale Onsekiz Mart Üniversitesi, Tıp Fakültesi Gastroenteroloji bölümü tarafından 01.01.2013 ve 31.12.2019 tarihleri arasında İBH tanısı nedeniyle takip edilen 18 yaş üstü 211 hasta retrospektif olarak incelendi. Hastaların yaş ortalaması, kadın-erkek oranı, sigara kullanımı, hastalığın şiddeti ve yerleşim yeri tespit edildi. Hastalarda gelişen lokal ve sistemik komplikasyonlar, uygulanan tedavi tipleri ve cerrahi tedavi nedenleri değerlendirildi.

Bulgular: İBH tanısı alan 211 hastadan; 158’i (%74,9) Ülseratif Kolit (ÜK), 53’ü (%25,1) Crohn hastalığı (CH) idi. ÜK hastalarında ortalama yaş 43,97±16,22, CH’de 42,30±14,73 idi. Tutulum yerleri değerlendirildiğinde ÜK için %58,4 distal kolit, %24,1 sol kolon, %16,5 oranında pankolit, %7 oranında Backwash ileit mevcuttu. Tedaviler açısından değerlendirildiğinde 152 (%72,0) hastada tek başına 5-aminosalicylate (5-ASA), 48 (%22,8) hastada tiyopürin, 20 (%9,5) hastada anti TNF kullanımı saptandı.

Sonuç: Bölgemizde sıklıkla görülen bu hastalıkların demografik, klinik ve laboratuvar özelliklerinin bilinmesi; tanı, takip, tedavi aşamalarında uygun yaklaşımların seçilmesinde ve ortaya çıkabilecek muhtemel komplikasyonların erken saptanmasında fayda sağlayabilir.

Anahtar kelimeler: İnflamatuvar Barsak Hastalığı, Ülseratif Kolit, Crohn Hastalığı, Hastalık Şiddet İndeksi, Karın Ağrısı, İshal

Keywords

İnflamatuvar Barsak Hastalığı Ülseratif Kolit Crohn Hastalığı Hastalık Şiddet İndeksi Karın Ağrısı İshal

References

  • 1. Geboes K, Van Eyken P. Inflammatory bowel disease unclassified and indeterminate colitis: the role of the pathologist. J Clin Pathol. 2009 Mar;62(3):201-5. http://dx.doi.org/10.1136/jcp.2008.059311
  • 2. Tremaine WJ. Diagnosis and treatment of indeterminate colitis. Gastroenterol Hepatol (N Y) 2011; 7: 826-8. https://pubmed.ncbi.nlm.nih.gov/22347823
  • 3. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol 2017; 15: 857-63. https://doi.org/10.1016/j.cgh.2016.10.039
  • 4. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54. https://doi.org/10.1053/j.gastro.2011.10.001
  • 5. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769-78. https://doi.org/10.1016/S0140-6736(17)32448-0
  • 6. Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol 2009; 43: 51-7. https://doi.org/10.1097/MCG.0b013e3181574636
  • 7. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5-36. https://doi.org/10.1155/2005/269076
  • 8. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818-25. https://doi.org/10.1016/0016-5085(85)90006-x
  • 9. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518-32. https://doi.org/10.1016/0016-5085(85)90006-x
  • 10. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29. https://doi.org/10.1056/NEJMra020831
  • 11. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, et al. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Populatio-Based Studies From Western Countries. Gastroenterology 2018; 155: 1079-89. https://doi.org/10.1053/j.gastro.2018.06.043
  • 12. Can G, Posul E, Yilmaz B, Can H, Korkmaz U, Ermis F, et al. Epidemiologic features of inflammatory bowel disease in Western Black Sea region of Turkey for the last 10 years: retrospective cohort study. Korean J Intern Med. 2019 May;34(3):519-529. https://doi.org/10.3904/kjim.2015.310
  • 13. Basar O, Ertugrul I, Ibis M, Ataseven H, Yuksel I, Ucar E, et al. The relation between mean platelet volume and inflammatory bowel disease activity. New Med J 2000:2;46-9. https://www.academia.edu/17566193/Inflamatuvar_Barsak_Hastaliklarinda_Ortalama_Trombosit_Hacmi_%C3%96l%C3%A7%C3%BCm%C3%BCn%C3%BCn_Hastalik_Aktivitesi_ile_Iliskisi (Accessed March 3, 2022)
  • 14. Tezel A, Dokmeci G, Eskiocak M, Umit H, Soylu AR. Epidemiological features of ulcerative colitis in Trakya, Turkey. J Int Med Res 2003; 31: 141-8. https://doi.org/10.1177/147323000303100211
  • 15. Lakatos PL, Vegh Z, Lovasz BD, David G, Pandur T, Erdelyi Z, et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 2013; 19: 1010-7. https://doi.org/10.1097/MIB.0b013e3182802b3e
  • 16. Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology 2019; 157: 647-59. https://doi.org/10.1053/j.gastro.2019.04.016
  • 17. Riegler G, Tartaglione MT, Carratú R, D'Incá R, Valpiani D, Russo MI, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci 2000; 45: 462-5. https://doi.org/10.1023/a:1005424603085
  • 18. Wang Y, Ouyang Q; APDW 2004 Chinese IBD working group. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. J Gastroenterol Hepatol 2007; 22: 1450-5. https://doi.org/10.1111/j.1440-1746.2007.04873.x
  • 19. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52: 2063-8. https://doi.org/10.1007/s10620-006-9691-2
  • 20. Prantera C, Davoli M, Lorenzetti R, Pallone F, Marcheggiano A, Iannoni C, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10: 41-5. https://doi.org/10.1097/00004836-198802000-00010
  • 21. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-5. https://doi.org/10.1097/00054725-200409000-00026
  • 22. Yeniceri M, Cakir Guney B, Kucuk I, Kara M, Yazgan Y, Kaplan M. Evaluation of hematological parameters as non-invasive markers in predicting the severity of the disease in ulcerative colitis. J Med Palliat Care. 2020; 1(3): 53-7. https://doi.org/10.47582/jompac.765810
  • 23. Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis 2012; 18: 573-83. https://doi.org/10.1080/00365520500217118
  • 24. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30. https://doi.org/10.1016/j.gastro.2003.08.025
  • 25. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139: 1147-55. https://doi.org/10.1053/j.gastro.2010.06.070
  • 26. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55: 1-15. https://doi.org/10.1136/gut.2005.081950a
  • 27. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold Ø, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006; 12: 543-50. https://doi.org/10.1097/01.MIB.0000225339.91484.fc
  • 28. Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-93. https://doi.org/10.1111/j.1572-0241.2008.02212.x
  • 29. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-30. https://doi.org/10.1136/gut.2005.084061
  • 30. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-36. https://doi.org/10.3748/wjg.v11.i46.7227
  • 31. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002; 8: 158-61. https://doi.org/10.3748/wjg.v8.i1.158
  • 32. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-9. https://doi.org/10.1038/ajg.2010.343
  • 33. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-9. https://doi.org/10.1055/s-2008-1040420
  • 34. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-6. https://doi.org/10.1038/ajg.2009.727
  • 35. Skrzydło-Radomańska B, Radwan P, Radwan-Kwiatek K. Retrospective analysis of hospital admissions of patients with ulcerative colitis and Crohn's disease from semi-rural and rural regions in the Department of Gastroenterology in Lublin between 2000- 2006. Ann Agric Environ Med 2008; 15: 193-7. https://pubmed.ncbi.nlm.nih.gov/19061254/
  • 36. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006; 12: 212-7. https://doi.org/10.1097/01.MIB.0000201098.26450.ae

Evaluation of clinical features, treatment options and complications in patients with inflammatory bowel disease

Year 2022, Volume: 7 Issue: 3, 64 - 70, 31.07.2022

Mücahit Ugar , Fatih Kamış , Yavuz Beyazıt

https://doi.org/10.22391/fppc.1088562

Abstract

Introduction: Inflammatory bowel diseases (IBD) form a group of inflammatory diseases occurring in genetically-susceptible people, which are characterized by chronic progression and whose cause is not fully known. The aim of this study is to determine the incidence of IBD in our region and examine the clinical characteristics, sociodemographic features, and treatment results of IBD patients.

Methods: Our study retrospectively investigates 211 patients over 18 years of age who were monitored for an IBD diagnosis between January 2, 2013, and December 31, 2019, by the gastroenterology department of Canakkale Onsekiz Mart University’s Faculty of Medicine. The mean age, female-male ratio, smoking habits, disease severity, and localization sites were identified for included patients. Local and systemic complications of administered treatment types and reasons for surgical treatment were also assessed in patients.

Results: Of the 211 patients with IBD diagnoses, 158 (74.9%) had Ulcerative Colitis (UC) and 53 (25.1%) had a diagnosis of Crohn’s disease (CD). The mean age at the time of diagnosis was 43.97±16.22 years for UC patients and 42.30±14.73 years for CD cases. The involvement sites for UC were distal colitis for 58.4% of patients, left colon for 24.1% of patients, pancolitis for 16.5% of patients, and backwash ileitis for 7% of patients. According to the treatment results, 152 (72.0%) patients took 5-aminosalicylate (5-ASA) alone, 48 (22.8%) took thiopurine, and 20 (9.5%) took anti-TNF.

Conclusion: Knowing the demographic, clinical, and laboratory features of these diseases, which are frequently seen in our region, can support the early identification of probable complications that may occur and the selection of appropriate approaches during diagnosis, treatment, and follow-up monitoring of these diseases.

Keywords: Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn’s Disease, Severity of Illness Index, Abdominal Pain, Diarrhea

Keywords

Inflammatory bowel diseases Ulcerative colitis Crohn's disease Severity of Illness index Abdominal Pain Diarrhea

References

  • 1. Geboes K, Van Eyken P. Inflammatory bowel disease unclassified and indeterminate colitis: the role of the pathologist. J Clin Pathol. 2009 Mar;62(3):201-5. http://dx.doi.org/10.1136/jcp.2008.059311
  • 2. Tremaine WJ. Diagnosis and treatment of indeterminate colitis. Gastroenterol Hepatol (N Y) 2011; 7: 826-8. https://pubmed.ncbi.nlm.nih.gov/22347823
  • 3. Shivashankar R, Tremaine WJ, Harmsen WS, Loftus EV Jr. Incidence and prevalence of Crohn's Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010. Clin Gastroenterol Hepatol 2017; 15: 857-63. https://doi.org/10.1016/j.cgh.2016.10.039
  • 4. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012; 142: 46-54. https://doi.org/10.1053/j.gastro.2011.10.001
  • 5. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet 2018; 390: 2769-78. https://doi.org/10.1016/S0140-6736(17)32448-0
  • 6. Tozun N, Atug O, Imeryuz N, Hamzaoglu HO, Tiftikci A, Parlak E, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol 2009; 43: 51-7. https://doi.org/10.1097/MCG.0b013e3181574636
  • 7. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5-36. https://doi.org/10.1155/2005/269076
  • 8. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88: 1818-25. https://doi.org/10.1016/0016-5085(85)90006-x
  • 9. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology 2004; 126: 1518-32. https://doi.org/10.1016/0016-5085(85)90006-x
  • 10. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29. https://doi.org/10.1056/NEJMra020831
  • 11. Shah SC, Khalili H, Gower-Rousseau C, Olen O, Benchimol EI, Lynge E, et al. Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Populatio-Based Studies From Western Countries. Gastroenterology 2018; 155: 1079-89. https://doi.org/10.1053/j.gastro.2018.06.043
  • 12. Can G, Posul E, Yilmaz B, Can H, Korkmaz U, Ermis F, et al. Epidemiologic features of inflammatory bowel disease in Western Black Sea region of Turkey for the last 10 years: retrospective cohort study. Korean J Intern Med. 2019 May;34(3):519-529. https://doi.org/10.3904/kjim.2015.310
  • 13. Basar O, Ertugrul I, Ibis M, Ataseven H, Yuksel I, Ucar E, et al. The relation between mean platelet volume and inflammatory bowel disease activity. New Med J 2000:2;46-9. https://www.academia.edu/17566193/Inflamatuvar_Barsak_Hastaliklarinda_Ortalama_Trombosit_Hacmi_%C3%96l%C3%A7%C3%BCm%C3%BCn%C3%BCn_Hastalik_Aktivitesi_ile_Iliskisi (Accessed March 3, 2022)
  • 14. Tezel A, Dokmeci G, Eskiocak M, Umit H, Soylu AR. Epidemiological features of ulcerative colitis in Trakya, Turkey. J Int Med Res 2003; 31: 141-8. https://doi.org/10.1177/147323000303100211
  • 15. Lakatos PL, Vegh Z, Lovasz BD, David G, Pandur T, Erdelyi Z, et al. Is current smoking still an important environmental factor in inflammatory bowel diseases? Results from a population-based incident cohort. Inflamm Bowel Dis 2013; 19: 1010-7. https://doi.org/10.1097/MIB.0b013e3182802b3e
  • 16. Piovani D, Danese S, Peyrin-Biroulet L, Nikolopoulos GK, Lytras T, Bonovas S. Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses. Gastroenterology 2019; 157: 647-59. https://doi.org/10.1053/j.gastro.2019.04.016
  • 17. Riegler G, Tartaglione MT, Carratú R, D'Incá R, Valpiani D, Russo MI, et al. Age-related clinical severity at diagnosis in 1705 patients with ulcerative colitis: a study by GISC (Italian Colon-Rectum Study Group). Dig Dis Sci 2000; 45: 462-5. https://doi.org/10.1023/a:1005424603085
  • 18. Wang Y, Ouyang Q; APDW 2004 Chinese IBD working group. Ulcerative colitis in China: retrospective analysis of 3100 hospitalized patients. J Gastroenterol Hepatol 2007; 22: 1450-5. https://doi.org/10.1111/j.1440-1746.2007.04873.x
  • 19. Rodgers AD, Cummins AG. CRP correlates with clinical score in ulcerative colitis but not in Crohn's disease. Dig Dis Sci 2007; 52: 2063-8. https://doi.org/10.1007/s10620-006-9691-2
  • 20. Prantera C, Davoli M, Lorenzetti R, Pallone F, Marcheggiano A, Iannoni C, et al. Clinical and laboratory indicators of extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10: 41-5. https://doi.org/10.1097/00004836-198802000-00010
  • 21. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-5. https://doi.org/10.1097/00054725-200409000-00026
  • 22. Yeniceri M, Cakir Guney B, Kucuk I, Kara M, Yazgan Y, Kaplan M. Evaluation of hematological parameters as non-invasive markers in predicting the severity of the disease in ulcerative colitis. J Med Palliat Care. 2020; 1(3): 53-7. https://doi.org/10.47582/jompac.765810
  • 23. Magro F, Rodrigues A, Vieira AI, Portela F, Cremers I, Cotter J, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis 2012; 18: 573-83. https://doi.org/10.1080/00365520500217118
  • 24. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125: 1508-30. https://doi.org/10.1016/j.gastro.2003.08.025
  • 25. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology 2010; 139: 1147-55. https://doi.org/10.1053/j.gastro.2010.06.070
  • 26. Stange EF, Travis SP, Vermeire S, Beglinger C, Kupcinkas L, Geboes K, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006; 55: 1-15. https://doi.org/10.1136/gut.2005.081950a
  • 27. Henriksen M, Jahnsen J, Lygren I, Sauar J, Kjellevold Ø, Schulz T, et al. Ulcerative colitis and clinical course: results of a 5-year population-based follow-up study (the IBSEN study). Inflamm Bowel Dis 2006; 12: 543-50. https://doi.org/10.1097/01.MIB.0000225339.91484.fc
  • 28. Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn's disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008; 103: 3082-93. https://doi.org/10.1111/j.1572-0241.2008.02212.x
  • 29. Wolters FL, Russel MG, Sijbrandij J, Ambergen T, Odes S, Riis L, et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-30. https://doi.org/10.1136/gut.2005.084061
  • 30. Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, et al. Extraintestinal manifestations in inflammatory bowel disease. World J Gastroenterol 2005; 11: 7227-36. https://doi.org/10.3748/wjg.v11.i46.7227
  • 31. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol 2002; 8: 158-61. https://doi.org/10.3748/wjg.v8.i1.158
  • 32. Vavricka SR, Brun L, Ballabeni P, Pittet V, Prinz Vavricka BM, Zeitz J, et al. Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort. Am J Gastroenterol 2011; 106: 110-9. https://doi.org/10.1038/ajg.2010.343
  • 33. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin Liver Dis 1991; 11: 31-9. https://doi.org/10.1055/s-2008-1040420
  • 34. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980; 79: 200-6. https://doi.org/10.1038/ajg.2009.727
  • 35. Skrzydło-Radomańska B, Radwan P, Radwan-Kwiatek K. Retrospective analysis of hospital admissions of patients with ulcerative colitis and Crohn's disease from semi-rural and rural regions in the Department of Gastroenterology in Lublin between 2000- 2006. Ann Agric Environ Med 2008; 15: 193-7. https://pubmed.ncbi.nlm.nih.gov/19061254/
  • 36. Jiang L, Xia B, Li J, Ye M, Yan W, Deng C, et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006; 12: 212-7. https://doi.org/10.1097/01.MIB.0000201098.26450.ae
There are 36 citations in total.

Details

Primary Language English
Subjects ​Internal Diseases
Journal Section Original Research
Authors

Mücahit Ugar 0000-0003-4944-3577

Fatih Kamış 0000-0003-2913-6166

Yavuz Beyazıt 0000-0001-6247-2714

Publication Date July 31, 2022
Submission Date March 16, 2022
Acceptance Date July 20, 2022
Published in Issue Year 2022 Volume: 7 Issue: 3

Cite

APA Ugar, M., Kamış, F., & Beyazıt, Y. (2022). Evaluation of clinical features, treatment options and complications in patients with inflammatory bowel disease. Family Practice and Palliative Care, 7(3), 64-70. https://doi.org/10.22391/fppc.1088562
AMA Ugar M, Kamış F, Beyazıt Y. Evaluation of clinical features, treatment options and complications in patients with inflammatory bowel disease. Fam Pract Palliat Care. July 2022;7(3):64-70. doi:10.22391/fppc.1088562
Chicago Ugar, Mücahit, Fatih Kamış, and Yavuz Beyazıt. “Evaluation of Clinical Features, Treatment Options and Complications in Patients With Inflammatory Bowel Disease”. Family Practice and Palliative Care 7, no. 3 (July 2022): 64-70. https://doi.org/10.22391/fppc.1088562.
EndNote Ugar M, Kamış F, Beyazıt Y (July 1, 2022) Evaluation of clinical features, treatment options and complications in patients with inflammatory bowel disease. Family Practice and Palliative Care 7 3 64–70.
IEEE M. Ugar, F. Kamış, and Y. Beyazıt, “Evaluation of clinical features, treatment options and complications in patients with inflammatory bowel disease”, Fam Pract Palliat Care, vol. 7, no. 3, pp. 64–70, 2022, doi: 10.22391/fppc.1088562.
ISNAD Ugar, Mücahit et al. “Evaluation of Clinical Features, Treatment Options and Complications in Patients With Inflammatory Bowel Disease”. Family Practice and Palliative Care 7/3 (July2022), 64-70. https://doi.org/10.22391/fppc.1088562.
JAMA Ugar M, Kamış F, Beyazıt Y. Evaluation of clinical features, treatment options and complications in patients with inflammatory bowel disease. Fam Pract Palliat Care. 2022;7:64–70.
MLA Ugar, Mücahit et al. “Evaluation of Clinical Features, Treatment Options and Complications in Patients With Inflammatory Bowel Disease”. Family Practice and Palliative Care, vol. 7, no. 3, 2022, pp. 64-70, doi:10.22391/fppc.1088562.
Vancouver Ugar M, Kamış F, Beyazıt Y. Evaluation of clinical features, treatment options and complications in patients with inflammatory bowel disease. Fam Pract Palliat Care. 2022;7(3):64-70.
 Download Cover Image

Family Practice and Palliative Care       ISSN 2458-8865       E-ISSN 2459-1505